Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D001943', 'term': 'Breast Neoplasms'}], 'ancestors': [{'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D001941', 'term': 'Breast Diseases'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'FACTORIAL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 452}}, 'statusModule': {'overallStatus': 'NOT_YET_RECRUITING', 'startDateStruct': {'date': '2026-06-01', 'type': 'ESTIMATED'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-11', 'completionDateStruct': {'date': '2030-11-30', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-11-14', 'studyFirstSubmitDate': '2025-11-14', 'studyFirstSubmitQcDate': '2025-11-14', 'lastUpdatePostDateStruct': {'date': '2025-11-18', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2025-11-18', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2030-11-30', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change in pain severity and interference as measured by the Brief Pain Inventory - Short Form', 'timeFrame': 'Baseline, 6 months, 12 months', 'description': 'The Brief Pain Inventory-Short Form (BPI-SF) will be used to assess pain severity and interference from pain across important life domains (e.g., general activity, work, relations with others). To calculate a pain severity score, the BPI-SF averages worst, least, average and current pain severity ratings on a 0 to 10 scale, with higher scores indicating more severe pain. To calculate a pain interference score, 7 items asking about interference from pain across different life domains will be averaged, with higher scores indicating higher pain interference.'}], 'secondaryOutcomes': [{'measure': 'Change in emotional distress, as measured by the PROMIS® Anxiety and Depression 4-item Short Forms', 'timeFrame': 'Baseline, 6 months, 12 months', 'description': 'For the PROMIS® Anxiety and Depression 4-item Short Forms (4a, v1.0) items are summed to create a raw score from 4 to 20 that is converted to a T-score. Responses are on a 5-point scale from "never" (1) to "always" (5). Higher scores indicate higher emotional distress.'}, {'measure': 'Change in fatigue, as measured by the PROMIS® Fatigue 6-item Short Form', 'timeFrame': 'Baseline, 6 months, 12 months', 'description': 'For the PROMIS® Fatigue 6-item Short Form (6a, v1.0) items are summed to create a raw score that is converted to a T-score. Participants are asked to think about the last week when responding to each item (e.g., "In the past 7 days, how run-down did you feel, on average?"), providing ratings on a scale from "not at all" (1) to "very much" (5). Sum scores may range from 6 to 30, with higher scores indicating higher fatigue.'}, {'measure': 'Change in physical function, as measured by the Five Times Sit to Stand Test (5xSST)', 'timeFrame': 'Baseline, 6 months, 12 months', 'description': 'The Five Times Sit to Stand Test (5xSST) assesses functional lower extremity strength, balance, risk of fall, functional decline, and frailty. The amount of time it takes a patient to sit and stand five times in succession with arms folded across their chest is averaged across three trials.'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Breast Neoplasms', 'Geriatric Oncology', 'Aromatase Inhibitors'], 'conditions': ['Breast Cancer, Hormone Receptor Positive, Aromatase Inhibitor-Associated Arthralgia']}, 'descriptionModule': {'briefSummary': 'Older women (≥65 years) with HR+ non-metastatic breast cancer experience high symptom burden and reduced quality of life during aromatase inhibitor (AI) therapy. This hierarchical 2×2 factorial randomized controlled trial will test two interventions: (1) a clinic-level geriatric oncology assessment and support program (GOAL-AI) and (2) a patient-level CBT-based coping skills training (CST-AI). The study aims to improve pain, symptom burden, and health-related quality of life compared to enhanced usual care.'}, 'eligibilityModule': {'sex': 'FEMALE', 'stdAges': ['OLDER_ADULT'], 'minimumAge': '65 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Female, age ≥65 years\n* HR+ non-metastatic breast cancer\n* Within 12 months of starting AI therapy\n* English-speaking\n* Able to provide consent\n\nExclusion Criteria:\n\n* Age \\<65 years\n* Metastatic cancer\n* Cognitive impairment preventing consent\n* Receiving care at multiple participating sites'}, 'identificationModule': {'nctId': 'NCT07232056', 'acronym': 'GOAL-AI', 'briefTitle': 'Geriatric Oncology Assessment and Coping Skills Training for Older Women on Aromatase Inhibitor Therapy', 'organization': {'class': 'OTHER', 'fullName': 'Duke University'}, 'officialTitle': 'Geriatric Oncology Assessment to Link With Support for Older Women Taking Adjuvant Aromatase Inhibitor Therapy', 'orgStudyIdInfo': {'id': 'Pro00118528'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'GOAL-AI + CST-AI', 'description': 'Combination of clinic-level geriatric assessment and CBT-based coping skills training.', 'interventionNames': ['Behavioral: GOAL-AI', 'Behavioral: CST-AI']}, {'type': 'EXPERIMENTAL', 'label': 'GOAL-AI alone', 'description': 'Clinic-level geriatric assessment and support only.', 'interventionNames': ['Behavioral: GOAL-AI']}, {'type': 'EXPERIMENTAL', 'label': 'CST-AI alone', 'description': 'CBT-based coping skills training only.', 'interventionNames': ['Behavioral: CST-AI']}, {'type': 'NO_INTERVENTION', 'label': 'Enhanced Usual Care', 'description': 'Standard care with educational materials.'}], 'interventions': [{'name': 'GOAL-AI', 'type': 'BEHAVIORAL', 'description': 'Clinic-level geriatric assessment and support program.', 'armGroupLabels': ['GOAL-AI + CST-AI', 'GOAL-AI alone']}, {'name': 'CST-AI', 'type': 'BEHAVIORAL', 'description': 'CBT-based coping skills training via telehealth.', 'armGroupLabels': ['CST-AI alone', 'GOAL-AI + CST-AI']}]}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Smrithi Divakaran, MBBS, MSPH', 'role': 'CONTACT', 'email': 'smrithi.divakaran@duke.edu', 'phone': '919-681-7695'}, {'name': 'Michael W Willis, BA', 'role': 'CONTACT', 'email': 'michael.w.willis@duke.edu', 'phone': '919-681-8437'}], 'overallOfficials': [{'name': 'Rebecca Shelby, PhD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Duke University'}]}, 'ipdSharingStatementModule': {'infoTypes': ['STUDY_PROTOCOL', 'SAP', 'ICF'], 'timeFrame': 'Data will be shared either at the time of publication or at the end of the performance period, whichever comes first. All data deposited with the Duke Research Data Repository will be retained for a minimum of 25 years according to their stated Retention Policy.', 'ipdSharing': 'YES', 'description': 'The following data will be preserved and shared: patient-reported data from study assessments, healthcare utilization data collected from the health record, AI adherence data collected via self-report and from the health record, physical function and geriatric assessment data collected by study staff in clinic and from the health record, and socio-demographic and medical data collected via patient report and health record.'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Duke University', 'class': 'OTHER'}, 'collaborators': [{'name': 'National Cancer Institute (NCI)', 'class': 'NIH'}], 'responsibleParty': {'type': 'SPONSOR'}}}}